D. Krasnojon

513 total citations
9 papers, 396 citations indexed

About

D. Krasnojon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, D. Krasnojon has authored 9 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in D. Krasnojon's work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). D. Krasnojon is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). D. Krasnojon collaborates with scholars based in Russia and United States. D. Krasnojon's co-authors include Alicia Clawson, Sergey Cheporov, G. Manikhas, Paul Bhar, А. Н. Махсон, William J. Gradishar, John R. McGuire, José Iglesias, WJ Gradishar and Michael Hawkins and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

D. Krasnojon

9 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Krasnojon Russia 5 348 160 77 40 30 9 396
Nancy Tray United States 6 135 0.4× 105 0.7× 58 0.8× 24 0.6× 60 2.0× 7 280
Laura Santos Spain 10 103 0.3× 94 0.6× 104 1.4× 10 0.3× 166 5.5× 22 350
J. De Waal Germany 5 331 1.0× 210 1.3× 98 1.3× 4 0.1× 73 2.4× 13 425
Mark Crozier United States 7 185 0.5× 30 0.2× 89 1.2× 25 0.6× 94 3.1× 10 435
Zhengzi Qian China 10 179 0.5× 42 0.3× 60 0.8× 41 1.0× 120 4.0× 29 415
Aiko Nagayama Japan 9 274 0.8× 100 0.6× 92 1.2× 14 0.3× 74 2.5× 27 394
Kyriaki Pliarchopoulou Greece 10 160 0.5× 46 0.3× 90 1.2× 13 0.3× 141 4.7× 14 351
Guillaume Gapihan France 9 124 0.4× 118 0.7× 48 0.6× 25 0.6× 166 5.5× 13 298
Naseer Qayum United Kingdom 11 247 0.7× 68 0.4× 25 0.3× 9 0.2× 89 3.0× 21 358
R. Adinin United States 6 314 0.9× 100 0.6× 113 1.5× 51 1.3× 234 7.8× 9 496

Countries citing papers authored by D. Krasnojon

Since Specialization
Citations

This map shows the geographic impact of D. Krasnojon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Krasnojon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Krasnojon more than expected).

Fields of papers citing papers by D. Krasnojon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Krasnojon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Krasnojon. The network helps show where D. Krasnojon may publish in the future.

Co-authorship network of co-authors of D. Krasnojon

This figure shows the co-authorship network connecting the top 25 collaborators of D. Krasnojon. A scholar is included among the top collaborators of D. Krasnojon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Krasnojon. D. Krasnojon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2012). Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer. 12(5). 313–321. 91 indexed citations
2.
3.
Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2011). Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.. Journal of Clinical Oncology. 29(27_suppl). 275–275. 8 indexed citations
4.
5.
Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2009). Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 27(22). 3611–3619. 260 indexed citations
6.
Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2008). Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 6(7). 172–172. 6 indexed citations
7.
Vukelja, Svetislava J., Joyce O’Shaughnessy, D. Krasnojon, et al.. (2008). Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1082–1082. 1 indexed citations
8.
9.
Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2007). Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1032–1032. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Tray Breakdown of academic impact, for papers by Laura Santos Breakdown of academic impact, for papers by J. De Waal Breakdown of academic impact, for papers by Mark Crozier Breakdown of academic impact, for papers by Zhengzi Qian Breakdown of academic impact, for papers by Aiko Nagayama Breakdown of academic impact, for papers by Kyriaki Pliarchopoulou Breakdown of academic impact, for papers by Guillaume Gapihan Breakdown of academic impact, for papers by Naseer Qayum Breakdown of academic impact, for papers by R. Adinin
Rankless by CCL
2026